Sant P. Chawla, MD, FRACP (he/him/his)

Medical Director
Sarcoma Oncology Center

Sant P. Chawla, MD holds medical licensure in both Texas and California, is board certified in Internal Medicine and Medical Oncology. He is a pioneering physisian whose work in sarcoma oncology has brought him several accolades and recognition as one of the world's leading authoritieies in medical treatment and clinical research for bone and soft-tissue sarcomas and sarcoma therapy. Dr. Chawla heads the Sarcoma Oncology Center in Santa Monica CA where he leads clinical cancer research effors and conducts groundbreaking clinical research in sarcomas, pancreactic carcinoma, gynecologic tumors, breast cancer, glioblastoma, malignant peripheral nerve sheath tumors, lung cancer and gastrointestinal tumors.

Poster(s):

• (P 111) INTERIM ANALYSIS OF A PHASE 1 STUDY USING IL12-FHAB WITH OPTIMIZED PHARMACOKINETICS

• (P 112) PHASE 1/2 STUDY OF YH001, A CTLA-4 ANTIBODY WITH THE SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ENVAFOLIMAB, WITH OR WITHOUT DOXORUBICIN IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA

• (P 116) UPDATE ON SAINT: RESULTS OF 100 PATIENTS TREATED WITH IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) AS FIRST LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA [NCT03138161]

• (P 117) INTERIM ANALYSIS OF PHASE 2 STUDY: A METRONOMIC REGIMEN USING GEMCITABINE, DOXORUBICIN, DOCETAXEL AND NIVOLUMAB FOR ADVANCED LEIOMYOSARCOMA (NCT04535713)

• (P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS

• (P 183) A PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (ANN) IN SUBJECTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS (STS) WITH PULMONARY METASTASES

• (P 184) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM IN SUBJECTS WITH ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MTD/RP2D

• (P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST

• (P 383) AI ANALYSIS SHOWS ENHANCED CCNG1 ONCOGENE EXPRESSION IN SARCOMA TUMORS AND SUPPORTS THE USE OF DELTAREX-G, A CCNG1 INHIBITOR, AS PLATFORM THERAPY FOR ADVANCED SARCOMA

• (P 439) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 COMBINED WITH CHEMOTHERAPY IN EWING SARCOMA: PRELIMINARY DATA FROM A PHASE 1 STUDY

• (P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY

• (P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)

• (P 553) A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS